Overview of ccRCC and Introduction to the CheckMate 9ER Trial
Toni Choueiri, MD, and Rohit Gosain, MD share their clinical experience treating patients with clear cell renal cell carcinoma (ccRCC) and provide a short summary of previously reported data from the CheckMate 9ER trial.
Now Viewing
EP: 1.Overview of ccRCC and Introduction to the CheckMate 9ER Trial
EP: 2.A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER Trial
EP: 3.CheckMate 9ER: Progression-free Survival, Overall Survival, and Objective
EP: 4.Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC
EP: 5.A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions
EP: 6.Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCC
EP: 7.Recap: Combination Therapy Shows Promise in Renal Cell Carcinoma
Related Videos
